Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Phase 2b Trial With an Open-label Extension to Determine the Safety and Efficacy of GH001 in Patients With Treatment-resistant Depression

NCT05800860 is registered in ClinicalTrials.gov with GH Research Ireland Limited as lead sponsor.

NCT NCT05800860
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05800860 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Phase 2b Trial With an Open-label Extension to Determine the Safety and Efficacy of GH001 in Patients With Treatment-resistant Depression
Lead sponsor
GH Research Ireland Limited
Phase
Phase 2
Overall status
Completed
Start date
May 24, 2023
Completion date
March 11, 2025
Enrollment
81 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

treatment-resistant depression